Huawei H1 2025: Net Profit Falls 32% to ¥37B as R&D Surges to ¥96.9B (22.7% of Revenue)

Huawei (Private) posted a punchy set of half-year figures on Friday: net profit sank 32% to 37 billion yuan (about $5.17 billion), even as sales inched up 4% to 427 billion yuan - the company's strongest first-half revenue since 2020.

What ate into the bottom line was a brutal ramp-up in research and development. Huawei ploughed 96.9 billion yuan into R&D in the first six months, up from 88.9 billion a year earlier. That R&D bill works out to roughly 22.7% of first-half revenue - a big slice, and a clear signal that the company is prioritising technology and supply-chain independence over near-term profitability.

The backdrop is familiar: U.S. restrictions on advanced chips since 2020 forced Huawei to double down on internal capabilities - everything from custom silicon to chipmaking tools. The Mate 60 series marked a comeback into high-end 5G phones in 2023 (mostly sold domestically), and the firm's H1 shipment tally shows that strategy is still China-centric: 26.6 million smartphones shipped, up 1.7% year-on-year, with about 95% destined for the China market.

Management didn't break out unit-level profit by business line for the period, so it's hard to tell which divisions are carrying the load. Still, the numbers lay out a few clear takeaways for market watchers:

- Heavy R&D spend has noticeably compressed headline profit despite modest revenue growth.
- The company remains highly reliant on the China market for handset volume, limiting near-term export exposure.
- The long-term play is tech self-reliance - big outlays now that may reduce dependence on foreign suppliers later, especially in chipmaking and equipment.

For public markets, Huawei's moves matter indirectly. Suppliers, rivals and semiconductor equipment makers that address Huawei's needs will see the ripple effects of its capex and R&D choices, and the firm's China-first handset footprint shifts competitive dynamics at home.

Numbers to keep in your head: 96.9 billion yuan on R&D, 37 billion yuan in net profit, and 427 billion yuan in revenue for H1 2025. Short-term profits took a hit. Long-term ambitions just got a lot clearer.